Hypergastrinemia in animals and man: Causes and consequences

Scandinavian Journal of Gastroenterology

Volumn 39, Issue 6, 2004, Pages 505-509

  Waldum, H L ^a   Fossmark, R ^a   Bakke, I ^a   Martinsen, T C ^a   Qvigstad, G ^a  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

GASTRIN; HISTAMINE H2 RECEPTOR ANTAGONIST; OMEPRAZOLE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PROTON PUMP INHIBITOR;

BACTERIAL INFECTION; DISEASE ACTIVITY; DISEASE COURSE; HELICOBACTER PYLORI; HUMAN; HYPERGASTRINEMIA; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SECRETION; REVIEW; STOMACH CARCINOMA; STOMACH PH; TARGET ORGAN; TRANSGENIC ANIMAL;

ANIMALS; GASTRIC ACID; GASTRIC MUCOSA; GASTRINS; HUMANS; RECEPTORS, GASTROINTESTINAL HORMONE; STOMACH DISEASES;

EID: 3142736006     PISSN: 00365521     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365520410005072     Document Type: Review

References (88)

1. Edkins JS. On the chemical mechanism of gastric acid secretion. Proc Soc Med (B) 1905;76:376.
2. Bayliss WM, Starling EH. The mechanism of pancreatic secretion. J Physiol 1902;28:325-53.
3. Gregory RA, Tracy HJ. The preparation and properties of gastrin. J Physiol (Lond) 1961;156:523-43.
4. McGuigan JE, Trudeau WL. Studies with antibodies to gastrin. Radioimmunoassay in human serum and physiological studies. Gastroenterology 1970;58:139-50.
5. Makhlouf GM, McManus JPA, Card WI. Action of pentapeptide (ICI 50 123) on gastric secretion in man. Gastroenterology 1966; 51:455-65.
6. Kahlson GE, Rosengren D, Svahn D, Thunberg R. Mobilization and formation of histamine in the gastric mucosa as related to acid secretion. J Physiol 1964;174:400-16.
7. Waldum HL, Kleveland PM, Sandvik AK. Effects of gastrin on isolated perfused stomach. In: Håkanson R, Sundler F, editors. The stomach as an endocrine organ. Erik Femstrøm Symposium Elsevier; 1991. p. 283-96.
8. Brenna E, Waldum HL. Studies of isolated parietal and enterochromaffin-like cells from the rat. Scand J Gastroenterol 1991;26: 1295-306.
9. Håkanson R, Böttcher G, Ekblad E, Panula P, Simonsson M, Dohlsten M, et al. Histamine in endocrine cells in the stomach. A survey of several species using a panel of histamine antibodies. Histochemistry 1986;86:5-17.
10. Waldum HL, Sandvik AK. Gastric functional and trophic receptors for CCK. In: Smith T, editor. Aspects of synaptic transmission: acetylcholine, sigma receptors, CCK and eicosanoids, neurotoxins. London: Taylor and Francis Ltd; 1993. p. 157-72.
11. Waldum HL, Sandvik AK, Brenna E, Petersen H. Gastrin-histamine sequence in the regulation of gastric acid secretion. Gut 1991;32:698-701.
12. Kleveland PM, Waldum HL, Larsson M. Gastric acid secretion in the totally isolated, vascularly perfused rat stomach. A selective muscarinic-1 agent does, whereas gastrin does not augment maximal histamine-stimulated acid secretion. Scand J Gastroenterol 1987;22:705-13.
13. Bakke I, Qvigstad G, Sandvik AK, Waldum HL. The CCK-2 receptor is located on the ECL cell, but not on the parietal cell. Scand J Gastroenterol 2001;36:1128-33.
14. Crean GP, Marshall MW, Rumsey RDE. Parietal cell hyperplasia induced by the administration of pentagastrin (ICI 50, 123) to rats. Gastroenterology 1969;57:47-56.
15. Bakke I, Qvigstad G, Brenna E, Sandvik AK, Waldum HL. Gastrin has a specific proliferative effect on the rat enterochromaffin-like cell, but not on the parietal cell: a study by elutriation centrifugation. Acta Physiol Scand 2000;169:29-7.
16. Håkanson R, Tielemans Y, Chen D, Andersson K, Mattsson H, Sundler F. Time-dependent changes in enterochromaffinlike cell kinetics in stomach of hypergastrinemic rats. Gastroenterology 1993;105:15-21.
17. Waldum HL, Kleveland PM, Sandvik AK, Brenna E, Syversen U, Bakke I, et al. The cellular localization of the cholecystokinin 2 (gastrin) receptor in the stomach. J Pharmacol Toxicol 2002;91: 359-62.
18. Higham AD, Bishop LA, Dimaline R, Blackmore CG, Dobbins AC, Varro A, et al. Mutations of RegIalpha are associated with enterochromaffin-like cell tumor development in patients with hypergastrinemia. Gastroenterology 1999;116:1310-8.
19. 2-receptor in normal human thyroid gland and medullary thyroid carcinoma. Eur J Endocrinol 2002;146:89-96.
20. Amiri-Mosavi A, Ahlman H, Tisell L-E, Wängberg B, Kölby L, Forssell-Aronsson E, et al. Expression of cholecystokinin-B/ gastrin receptors in medullary thyroid cancer. Eur J Surg 1999; 165:628-31.
21. 2+ mobilization and clonal growth in small cell lung cancer cells. Cancer Res 1992; 52:6031-5.
22. Guilloteau D, Perdrisot R, Calmettes C, Bauljeu JI, Lecomte P, Kaphan G, et al. Diagnosis of medullary carcinoma of the thyroid (MCT) by calcitonin assay using monoclonal antibodies: criteria for the pentagastrin stimulation test in hereditary MCT. J Clin Endocrinol Metab 1990;71:1064-7.
23. Håkanson R, Axelson J, Persson P, Sundler F. Which effects of antral gastrin are physiological? In: Bali JP, Martinez J, editors. Gastrin and cholecystokinin. Chemistry, physiology and pharmacology. Amsterdam, Elsevier; 1987. p. 161-78.
24. Smith AM, Watson SA. Gastrin and gastrin receptor activation: an early event in the adenoma-carcinoma sequence. Gut 2000;47: 8204.
25. Seva C, Dickinson CJ, Yamada T. Growth-promoting effects of glycine-extended progastrin. Science 1994;265:410-2.
26. Trudeau WL, McGuigan JE. Relations between serum gastrin levels and rates of gastric hydrochloric acid secretion. N Engl J Med 1971;284:408-12.
27. Walsh JW, Richardson CT, Fordtran JS. pH dependence of acid secretion and gastrin release in normal and ulcer subjects. J Clin Invest 1975;55:462-8.
28. Wilder-Smith CH, Spirig C, Krech T, Merk HS. Bactericidal factors in gastric juice. Eur J Gastroenterol Hepatol 1992;4:885-91.
29. Moss SF, Calam J. Acid secretion and sensitivity to gastrin in patients with duodenal ulcer: effect of eradication of Helicobacter pylori. Gut 1993;34:888-92.
30. Levi S, Beardshall K, Haddad G, Playford R, Ghosh P, Calam J. Campylobacter pylori and duodenal ulcers: the gastrin link. Lancet 1989;1:1167-8.
31. Katelaris PH, Seow F, Lin BPC, Napoli J, Ngu MC, Jones DB. Effect of age, Helicobacter pylori infection, and gastritis with atrophy on serum gastrin and gastric acid secretion in healthy men. Gut 1993;34:1032-7.
32. Waldum HL, Amestad JS, Brenna E, Eide I, Syversen U, Sandvik AK. Marked increase in gastric acid secretory capacity after omeprazole treatment. Gut 1996;39:649-53.
33. Sandvik AK, Waldum HL, Kleveland PM, Schulze Søgnen B. Gastrin produces an immediate and dose-dependent histamine release preceding acid secretion in the totally isolated, vascularly perfused rat stomach. Scand J Gastroenterol 1987;22:803-8.
34. Blair AJ, Richardson CT, Walsh JN, Feldman M. Variable contribution of gastrin to gastric acid secretion after a meal in humans. Gastroenterology 1987;92:944-99.
35. Brenna E, Waldum HL. Trophic effect of gastrin on the enterochromaffin-like cells of the rat stomach: establishment of a dose response relationship. Gut 1992;33:1303-6.
36. Sjöblom S-M, Sipponen P, Karonen S-L, Järvinen HJ. Argyrophil cell hyperplasia and carcinoid tumours in oxyntic mucosa of the stomach. Dependence on duration of pernicious anaemia. Eur J Gastroenterol Hepatol 1991;31:153-7.
37. Zollinger RM, Ellison EH. Primary peptic ulcerations of the jejunum associated with islet cell tumors of the pancreas. Ann Surg 1955;142:709-28.
38. Roy PK, Venzon DJ, Feigenbaum KM, Koviack PD, Bashir S, Ojeaburu JV, et al. Gastric secretion in Zollinger-Ellison syndrome. Correlation with clinical expression, tumor extent and role in diagnosis - a prospective NIH study of 235 patients and a review of 984 cases in the literature. Medicine (Baltimore) 2001; 80:189-222.
39. Metz DC, Pisegna JR, Fishbeyn VA, Benya RV, Feigenbaum KM, Koviack PD, et al. Currently used doses of omeprazole in Zollinger-Ellison syndrome are too high. Gastroenterology 1992; 103:1498-508.
40. Cadiot G, Vissuzaine C, Potet F, Mignon M. Fundic argyrophil carcinoid tumor in a patient with sporadic-type Zollinger-Ellison syndrome. Dig Dis Sci 1995;40:1275-8.
41. Lehy T, Cadiot G, Mignon M, Ruszniewski P, Bonfils S. Influence of multiple endocrine neoplasia type 1 on gastric endocrine cells in patients with the Zollinger-Ellison syndrome. Gut 1992; 33:1275-9.
42. Wormsley KG, Grossman MI. Maximal histalog test in control subjects and patients with peptic ulcer. Gut 1965;6:427-35.
43. Rauws EAJ, Tytgat GNJ. Cure of duodenal ulcer associated with eradication of Helicobacter pylori. Lancet 1990;335:1233-5.
44. Martinsen TC, Nesjan N, Rønning K, Sandvik AK, Waldum HL. The peroxisome-proliferator ciprofibrate induces hypergastrinemia without raising gastric pH. Carcinogenesis 1996;17:2153-5.
45. Gavey CJ, Smith JTL, Nwokolo CU, Pounder RE. Clofibrate raises human 24 h intragastric acidity but does not affect plasma gastrin concentration. Br J Clin Pharmacol 1990;29:473-7.
46. Waldum HL, Kvetnoi I, Sylte R, Schulze B, Martinsen TC, Sandvik AK. The effect of the peroxisome proliferator ciprofibrate on the gastric mucosa and particular the gastrin (G) cell. J Mol Endocrinol 1998;20:111-7.
47. Hammer TA, Sandvik AK, Waldum HL. Potentiating hypergastrinemic effect by the peroxisome proliferator ciprofibrate and omeprazole in the rat. Scand J Gastroenterol 1998;33:595-9.
48. Wang TC, Dangler CA, Chen D, Goldenring JR, Koh T, Raychowdhury R, et al. Synergistic interaction between hypergastrinemia and Helicobacter infection in a mouse model of gastric carcinoma. Gastroenterology 2000;118:36-47.
49. Korman MG, Strickland RG, Hansky J. Serum gastrin in chronic gastritis. Br Med J 1971;2:16-8.
50. Delle Fave G, Annibale B, Franceschi M, Quatrini M, Cassetta MR, Torsoli A. Omeprazole versus famotidine in the short-term treatment of duodenal ulcer disease. Aliment Pharmacol Ther 1992;6:469-578.
51. Creutzfeldt W, Lamberts R, Stöckmann F, Brunner G. Quantitative studies of gastric endocrine cells in patients receiving long-term treatment with omeprazole. Scand J Gastroenterol 1989;24: 122-8.
52. Meuwissen SGM, Ridwan BU, Hasper HJ, Innemee G. Hypertrophic protein-losing gastropathy. A retrospective analysis of 40 cases in The Netherlands. Scand J Gastroenterol 1992; 27:1-7.
53. Waldum HL, Rørvik H, Falkmer S, Kawase S. Neuroendocrine (ECL-cell) differentiation of spontaneous gastric carcinomas of cotton rats (Sigmodon hispidus). Lab Anim Sci 1999;49:241-7.
54. Mattsson H, Havu N, Brautigam J, Carlsson K, Lundell L, Carlsson E. Partial gastric corpectomy results in hypergastrinemia and development of gastric enterochromaffin-like cell carcinoids in the rat. Gastroenterology 1991;100:311-9.
55. Pedersen JH, Wille-Jørgensen P. Secretion of gastric acid and serum gastrin following antral exclusion in man. Acta Chir Scand 1980;146:615-7.
56. Sandvik AK, Waldum HL. The CCK-B (gastrin) receptor regulates gastric histamine release and acid secretion. Am J Physiol 1991;260:G925-G8.
57. 2-receptor antagonists. Aliment Pharmacol Ther 1990;4:15-27.
58. Sandvik AK, Mårvik R, Evans D, Waldum HL, Dimaline R. Gastrin regulates histidine decarboxylase (HDC) activity and mRNA abundance in the rat. Am J Physiol 1994;267:G254-G8.
59. Ryberg B, Tielemans Y, Axelson J, Carlsson E, Hakanson R, Mattson H, et al. Gastrin stimulates the self-replication rate of enterochromaffin-like cells in the rat stomach. Effects of omeprazole, ranitidine and gastrin-17 in intact and antrectomized rats. Gastroenterology 1990;99:935-42.
60. Waldum HL, Lehy T, Brenna E, Sandvik AK, Petersen H, Søgnen BS, et al. Effect of the histamine-1 antagonist astemizole alone or with omeprazole on rat gastric mucosa. Scand J Gastroenterol 1991;26:23-35.
61. Qvigstad G, Arnestad JS, Brenna E, Waldum HL. Treatment with proton pump inhibitors induces tolerance to histamine 2 receptor antagonists in Helicobacter pylori-negative patients. Scand J Gastroenterol 1998;33:1244-8.
62. Pisegna JR, Norton JA, Slimak GG, Metz DC, Maton PN, Gardner JD, et al. Effects of curative gastrinoma resection on gastric secretory function and antisecretory drug requirement in the Zollinger-Ellison syndrome. Gastroenterology 1992;102: 767-78.
63. Havu N. Enterochromaffin-like cell carcinoids of gastric mucosa in rats after life-long inhibition of gastric acid secretion. Digestion 1986;35 Suppl:42-55.
64. Havu N, Mattsson H, Ekman L, Carlsson E. Enterochromaffin-like cell carcinoids in the rat gastric mucosa following long-term administration of ranitidine. Digestion 1990;45:189-95.
65. Hirayama F, Takagi S, Iwao E, Yokayama Y, Haga K, Hanada S. Development of poorly differentiated adenocarcinoma and carcinoid due to long-term Helicobacter pylori colonization in Mongolian gerbils. J Gastroenterol 1999;34:450-4.
66. Soga J, Tazawa K, Kanahara H, Kraide K. Some characteristic features of spontaneous argyrophil cell carcinoids in glandular stomach of praomys (Mastomys) natalensis. GANN Monograph 1969;8:15-26.
67. Schaffer K, McBride EW, Beinborn M, Kopin AS. Interspecies polymorphisms confer signalling activity to the Mastomys CCK-B/gastrin receptor. Gastroenterology 1997;112:402A.
68. Wängberg B, Nilsson O, Theodorsson E, Modlin IM, Dahlstrøm A, Ahlman H. Are enterochromaffin-like cell tumours reversible? An experimental study on gastric carcinoids in Mastomys induced by histamine-receptor blockade. Reg Pept 1995;56:19-33.
69. Säfholm C, Havu N, Forssell H, Sundell G, Mattsson H. Effect of 7 years' daily oral administration of omeprazole to beagle dogs. Digestion 1994;55:139-47.
70. Waldum HL, Brenna E, Martinsen TC. Safety of proton pump inhibitors. Aliment Pharmacol Ther 2000;14:1537-8.
71. 2 blockade. Gut 1986;27:1338-46.
72. Modlin IM, Lye KD, Kidd M. Carcinoid tumors of the stomach. Surg Oncol 2003;12:153-72.
73. Kokkola A, Sjöblom SM, Haapiainen R, Sipponen P, Puolakkainen P, Järvinen H. The risk of gastric carcinoma and carcinoid tumours in patients with pernicious anaemia. A prospective follow-up study. Scand J Gastroenterol 1998;33:88-92.
74. Zamcheck N, Grable E, Ley A, Norman L. Occurrence of gastric cancer among patients with pernicious anemia at the Boston City Hospital. N Engl J Med 1955;252:1103-10.
75. Waldum HL, Petersen H, Brenna E. Gastrin and gastric cancer. Eur J Gastroenterol Hepatol 1992;4:801-11.
76. Waldum HL, Haugen OA, Isaksen C, Mecsei R, Sandvik AK. Are diffuse gastric carcinomas neuroendocrine tumours (ECL-omas)? Eur J Gastroenterol Hepatol 1991;3:245-9.
77. Waldum HL, Aase S, Kvetnoi I, Brenna E, Sandvik AK, Syversen U, et al. Neuroendocrine differentiation in human gastric carcinoma. Cancer 1998;83:435-44.
78. Qvigstad G, Sandvik AK, Brenna E, Aase S, Waldum HL. Detection of chromogranin A in human gastric adenocarcinomas using a sensitive immunohistochemical technique. J Histochem 2000;32:551-6.
79. Qvigstad G, Qvigstad T, Westre B, Sandvik AK, Brenna E, Waldum HL. Neuroendocrine differentiation in gastric adenocarcinomas associated with severe hypergastrinemia and/or pernicious anemia. APMIS 2002;110:132-9.
80. Waldum HL, Brenna E, Kleveland PM, Sandvik AK. Gastrin - physiological and pathophysiological role: clinical consequences. Dig Dis Sci 1995;13:25-38.
81. The Eurogast Study Group., An international association between Helicobacter pylori infection and gastric cancer. Lancet 1993;341:1359-62.
82. Waldum HL, Sandvik AK, Brenna E. Gastrin, the enterochromaffinlike cell and gastric tumors. [Letter]. Gastroenterology 1993;105:1264-5.
83. Hansen S, Vollset SE, Ardill JES, El-Omar E, Melby K, Aase S, et al. Hypergastrinemia is a strong predictor of distal gastric adenocarcinoma among Helicobacter pylori infected persons. Gastroenterology 1997;112:A575.
84. Sato Y, Iwafuchi M, Ueki J-I, Yoshimura A, Mochizuki T, Motoyama H, et al. Gastric carcinoid tumors without autoimmune gastritis in Japan. A relationship with Helicobacter pylori infection. Dig Dis Sci 2002;47:579-85.
85. Moss SF, Sood S. Helicobacter pylori. Curr Opin Infect Dis 2003;16:445-51.
86. Galés C, Sanchez D, Poirot M, Pyronnet S, Buscail L, Cussac D, et al. High tumorigenic potential of a constitutively active mutant of the cholecystokinin 2 receptor. Oncogene 2003;22:6081-9.
87. Waldum HL, Brenna E. Review article: is profound acid inhibition safe. Aliment Pharmacol Ther 2000;14:15-22.
88. Waldum HL, Brenna E, Sandvik AK. Long-term safety of proton pump inhibitors: risks of gastric neoplasia and infections. Expert Opin Drug Safety 2002;1:29-38.